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Background: Lateral epicondylalgia (LE) defines a condition of varying degrees of pain near the lateral epicondyle.
Studies on the management of LE indicated unexplained variations in the use of pharmacologic, non-
pharmacological and surgical treatments.
The main aim of this paper was to develop and evaluate clinical quality measures (QMs) or quality indicators,
which may be used to assess the quality of the processes of examination, education and treatment of patients
with LE.
Methods: Different QMs were developed by a multidisciplinary group of experts in Quality Management of
Health Services during a period of one year. The process was based following a 3-step model: i) review and
proportion of existing evidence-based recommendations; ii) review and development of quality measures; iii)
pilot testing of feasibility and reliability of the indicators leading to a final consensus by the whole panel.
Results: Overall, a set of 12 potential indicators related to medical and physical therapy assessment and
treatment were developed to measure the performance of LE care. Different systematic reviews and randomized
control trials supported each of the indicators judged to be valid during the expert panel process. Application of
the new indicator set was found to be feasible; only the measurement of two quality measures had light
barriers. Reliability was mostly excellent (Kappa > 0.8).
Conclusions: A set of good practice indicators has been built and pilot tested as feasible and reliable. The chosen
3-step standardized evidence-based process ensures maximum clarity, acceptance and sustainability of the developed
indicators.
Keywords: Lateral epicondylalgia, Quality of care, Recommendations, Quality measures, Clinical quality indicatorsBackground
Lateral epicondylalgia (LE), also known as tennis elbow
or lateral epicondylitis, defines a condition of varying
degrees of pain or point tenderness on or near the lateral
epicondyle. Functional use of the involved upper extremity,
especially during gripping activities usually exacerbates pain
symptoms [1,2]. Although LE has been traditionally defined
as an inflammatory process, several more recent studies
have shown that the pathophysiology of this process is
degenerative in nature [3-5]. Regardless of the aetiology,
LE represents a pathology that accounts for lost recreation
time, decreased quality of life, and work-related disability* Correspondence: franminaya@mvclinic.es
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distribution, and reproduction in any mediumclaims, and LE also has widespread social, financial, and
clinical implications [6].
In the past, studies on the management of LE indi-
cated substantial and unexplained variations in the use
of pharmacologic, non-pharmacological and surgical
treatments [7,8]. Currently, there is convincing evidence
demonstrating that multifactorial intervention programs
involving a multidisciplinary team are effective in reducing
both pain and disability of patients with lateral epicondy-
lalgia [7,9]. However, little is still known about the degree
of implementation of best practices recommendations for
these patients. This study was designed to address this
void of knowledge by developing quality measures (QMs)
for LE care [10].
QMs, or quality indicators, enable the user to quantify
the quality of a selected aspect of care by comparing itCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Thus, QMs can measure the performance of an individual
facility over time, compare the degree of implementation
of the best practices care between different health care
providers, and identify areas for improvement [12].
Methodological approaches to QMs’ development have
been described. Important attributes of high quality QMs
are their validity, their feasibility and their reliability.
Furthermore, they need to be easily understandable for
providers and achievable [13,14].
The objective of this paper was to develop a set of valid
and understandable clinical QMs that may be used to
assess the degree of implementation of the best processes
of examination, education and treatment of patients with
LE, and to pilot test their feasibility and reliability.
Methods
For the development of these evidence-based quality
indicators, we assembled a multidisciplinary panel of
recognized experts from the disciplines of traumatology,
nursing, physical therapy and psychopedagogy. The study
design and methods were reviewed and approved by the
Academic Review Committee of Quality Management
Program at the Faculty of Medicine of University of Murcia
(Murcia, Spain).
Research into quality of care, together with epidemio-
logical expertise, helped ensure methodological integrity
of the clinical indicators and the ensuing sound approach
to data collection and data analysis. The 6-member panel
included people from geographically diverse regions
including rural and urban areas.
We used a 3-step process to define the QMs (Figure 1).
First, we performed literature reviews to provide the
existing evidence-based recommendations in relation
to the three main components of LE care (examination,
education and treatment). Secondly, we reviewed the
existing QMs, identified evidence-based recommenda-
tions no covered by existing QMs and developed new
ones to cover all evidence-based recommendations. Thirdly,
we tested for feasibility and reliability of the accepted set
of QMs.
Review and proportion of existing evidence-based best
recommendations
A working group of panel members performed a compre-
hensive literature search to identify basic systematic reviews
(SRs) and clinical practice guidelines (CPG) that pertained
to LE care. Literature searches of both reviews and guide-
lines were conducted in the following databases over the
10 previous years (2001–2011): Medline, Cochrane Library
and Ovid, PEDro and ENFISPO. Additionally, searches
of clinical guidelines were performed using the following
specific guidelines databases: National Guideline Clearing-
house of AHRQ [11], the Scottish IntercollegiateGuidelines Network (SIGN) [15], the New Zealand Guide-
lines Group (NZGG) [16], National Institute for Health
and Clinical Excellence (NICE) [17], and GuiaSalud [18].
The working group retained recommendations which
had supporting evidence level A (one or more randomized
controlled trials, with or without systematic review) or
B (significant observational studies), with strength of
recommendations categorized as strong or weak according
to specific classifications, also taking into account a positive
balance between the desirable and undesirable conse-
quences and the lower costs of the alternative management
strategies [19]. To facilitate the next phase, we agreed to
provide a summary of the recommendations stating the
population to which these applied to and the process of
care measured. Thus, when it was possible, we created a
phrase using the structure IF-THEN.Review and development of quality indicators
Initially, the working group performed a comprehen-
sive search of quality indicators in the United States’
National Quality Measures Clearinghouse of the AHRQ
and in articles indexed in the following databases for
the 10 previous years (2001–2011): Medline, Scopus
and Psycinfo. For each of the existing indicators, the
working group provided an objective and a summary
of the available evidence, in order to assess whether to
support or refute them.
The working group elaborated new clinical indicators or
adapted existing ones when valid indicators were lacking
for some of the recommendations selected during the first
phase. Standardized reports of potential indicators were
suggested by the working group to facilitate discussion
within the whole panel before selection.
Following a proposal of the Agency for Healthcare
Research and Quality (AHRQ) on measure attributes
of the National Quality Measures Clearinghouse [11], the
report included: name; domain (process, access) and com-
ponent of health care quality to be covered (examination,
educational or therapeutic interventions); description of
the indicator, including definition of a suitable patient for
whom the quality is valid (included and excluded popula-
tion for numerator and denominator); evidence supporting
the indicator, including recommendations, evidence
level and strength of the recommendation and references
(original publications, guidelines, indicators and consensus
statements); data source and method of measurement
(review of medical record audits); computation of the
measure (rate or proportion). Figure 2 shows this stan-
dardized report as applied to an indicator.
The panel discussed the validity of each of the proposed
measures and retained those with adequate evidence of
the good practice measured and achievable or with the
indicator compliance under control of providers.
Review of existing evidence  
(guidelines, indicators and 
publications)
Develop of a set of potential 
indicators by WG-I
Indicators rated as valid
Assess of indicators reliability and 
feasibility using 80 patients per 
centre for each group
Indicators rated as valid, reliable 
and feasible
Review and modification of 




Figure 1 Diagram of the 3-step process developed to define the quality measures.
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The set of quality measures was them pilot tested by two
members of the panel to check whether the measure-
ment of performance of healthcare providers by the
QMs was feasible and reliable on a routine basis. This
study was conducted in three hospitals located in Barce-
lona, Vigo (Galicia) and Madrid. Each measure had its
own eligibility criteria, depending on the type of patients
it was aimed at. We selected only a randomized sample of
80 patients with LE who had received treatment during
the 12 month time period before the testing date as we
assumed that all QMs could have the minimal sample size
of 15 patients [20]. The database of medical records
belonging to each participant centre and diagnostic codes
(CMBD) were used for identifying subjects and selecting
the sample.
To test for feasibility of the QMs the two examiners
reviewed databases and selected medical records, report-
ing when it was not possible to assess some QMs and
related reasons. Predictable reasons encountered were:
difficulty to identify cases or misreported information in
medical records.Intra-rater and inter-rater designs were used to examine
the reliability of QMs. To test for intra-rater reliability, an
examiner assessed each QM in two occasions spaced out
over a period of 7 days. To test inter-rater reliability, an
additional examiner carried out assessments using the
same subjects’ medical records. Reliability indexes were
determined through the calculation of the Kappa index
using SPSS v.15. Alternatively, we used the general agree-
ment percentage when occurrence or absence of evaluated
processes of care was higher than 85%, because Kappa
index could be biased. We interpreted Kappa levels using
established conventions: values ranging from 0.40 to 0.59
may be considered moderate, 0.60 to 0.79 substantial,
and ≥ 80 excellent [21]. When the values of the Kappa
index were less than 0.60 or the values of the general
agreement index where less than 0.95, the quality indica-
tors were reviewed by the whole panel.Results
Table 1 includes the recommendations identified in the
first phase, and their evidence level and strength. None
Figure 2 Exemplary presentation of standardized report for an evidence-based quality measure.
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total of 12 potential QMs were created and accepted for
the pilot testing: 3 were related to assessment interven-
tions, 1 to educational interventions and 8 to therapeutic
interventions (Table 2).Feasibility and reliability
In the pilot testing, items with feasibility problems were
evidenced for 2 QMs, due to a lack of specific information
in medical records. They are indicated in Table 2. For
example, this occurred in the QM ‘Surgery intervention in
Table 1 Evidence-based recommendations for lateral epicondylalgia care
Components of care Evidence-based recommendations Evidence level / strength
recommendation
I. Patient exam
Physical Examination 1. IF a patient begins a treatment for lateral epicondylalgia,
THEN evidence that the affected tendon was examined
should be documented (at least orthopaedic tests).
B / Strong [22]
Pain and functional assessment 2. IF a patient has symptomatic lateral epicondylalgia, THEN
pain should be assessed (at least the intensity level) upon
initiation of a new treatment at least once.
B / Strong [23,39,43]
3. IF a patient has symptomatic lateral epicondylalgia, THEN
functional status should be assessed upon initiation of a
new treatment at least once.
B / Strong [23,39,43]
II. Educational interventions
Education 4. IF a patient has symptomatic lateral epicondylalgia, THEN
education about self-management of risk factors (repetitive
movements, etc.) should be given or recommended at least once.
A / Strong [28-30]
III. Therapeutic interventions
1. Pharmacological therapy
First line 5. IF a patient is started on pharmacological therapy to treat
lateral epicondylalgia, THEN NSAIDs should be tried first.
B / Weak [31,32]
Prophylaxis 6. IF a patient with a risk factor for GI bleeding (age ≥75,
peptic ulcer disease, history of GI bleeding) is treated with
a NSAID, THEN he or she should be treated concomitantly
with inhibitors (e.g. proton pump inhibitor, misoprostol, etc.).
A / Strong [35]
2. Physical therapy
First line 7. IF a patient is started on physical therapy to treat lateral
epicondylalgia, THEN a program of exercise therapy
(training epicondyle muscles excentrically and concentrically)
should be tried first.
A / Strong [24,25,36-38]
8. IF a patient is started on physical therapy to treat lateral
epicondylalgia, THEN manual therapy by mobilization with
movement should be tried first.
A / Strong [26,39]
9. IF a patient is started on physical therapy to treat lateral
epicondylalgia, THEN laser therapy should be tried first.
A / Strong [40]
Time to referral 10. IF a patient is treated with corticosteroid injection for
lateral epicondylalgia, THEN a multimodal program of
physical therapy should be initiated early before 14 days.
A / Strong [43]
3. Other therapeutic interventions
First line 11. IF a patient is treated with platelet-rich plasma for lateral
epicondylalgia, THEN infiltration into the extensor digitorum
communis tendon by peppering technique should be
recommended.
B / Strong [42,44-46]
Surgery 12. IF a patient was symptomatic after a minimum of 6–12
months of conservative therapies, THEN surgery should be
recommended.
A / Strong [47-49]
Evidence level A (one or more randomized controlled trials, with or without systematic review) and B (significant observational studies).
Strength of recommendations strong and weak according to specific classifications.
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12 months of conservative therapies’ because pain assess-
ment was not measurable on some patients. Reliability in-
dexes are displayed in Table 2 for each potential indicator.
All indexes indicated substantial to excellent agreement.
Supporting evidence
Brief descriptions of the literature that supports the criter-
ion of quality for each of the indicators are provided below.Patient examination
Physical examination
Patients with cervical radiculopathy, proximal neurovascu-
lar entrapment and radial tunnel syndrome [2] may com-
plain of the same symptoms as patients with LE. However,
there is no “gold standard” for the diagnosis of LE, and
orthopaedic tests such as pain with resisted wrist extension
(Cozen’s sign) are traditionally recommended for differen-
tial diagnosis [22].
Table 2 Quality measures for lateral epicondylalgia care and their reliability
Clinical quality measures n Kappa index General agreement percentage (%)
Inter-rater Intra-rater Inter-rater Intra-rater
I. Patient exam
1. Physical examination: percentage of patients with LE
for whom the affected tendon was examined (at least
orthopedic tests).
80 - - 100 100
2. Pain assessment: percentage of patients with LE who
had pain assessment upon initiation of a new
treatment.
80 - - 95 100
3. Functional assessment: percentage of patients with LE
who had functional assessment upon initiation of a
new treatment.
80 - - 85 95
II. Educational interventions
1. Education: percentage of patients with LE for whom
their health provider gave them education and counselling
for risk factor reduction strategies.
80 0.8 0.9 - -
III. 1. Pharmacological therapy
1. Pharmacological therapy for LE: percentage of patients
who received pharmacological therapy for LE and who
received NSAIDs as first line.
75 - - 100 100
2. Prophylaxis for gastrointestinal bleeding: percentage of
patients with NSAIDs for LE who concomitantly received
inhibitors (e.g. proton pump inhibitor, misoprostol, etc.).
24 0.9 1 - -
III. 2. Physical therapy
1. Physical therapy for LE: percentage of patients who
received physical therapy for LE and who received a
program of exercise therapy as first line.
42 - - 95 100
2. Physical therapy for LE: percentage of patients who
received physical therapy for LE and who received manual
therapy as first line.
42 0.9 1 - -
3. Physical therapy for LE: percentage of patients who
received physical therapy for LE and who received laser
therapy as first line.
42 0.9 1 - -
4. Time of referral: percentage of patients with LE who
received corticosteroid injection and who initiated a
multimodal program of physical therapy within 14 days
of the injection.
17 1 1 - -
III. 3. Other therapeutic interventions
1. Platelet-rich plasma (PRP) therapy for LE: percentage
of patients who received PRP therapy for LE and who
received PRP therapy as first line (*).
1 N/A. N/A. N/A. N/A.
2. Surgery intervention for LE: percentage of patients
who were symptomatic after a minimum of 6–12
months of conservative therapies and who underwent
surgery (*).
14 N/A. N/A. N/A. N/A.
N/A. Not applicable.
-: Index not calculated. The general agreement percentage was used when occurrence or absence of evaluated processes of care was higher than 85%.
*.QMs in the text which had slight feasibility problems.
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The literature review failed to identify clinical studies that
evaluated relations between outcomes and assessment of
pain or functional limitations. However, because improve-
ment of pain and function are two primary goals in the
treatment of LE [23], it seems that these parameters are
essential for clinical decision making.Educational interventions
A variety of factors, such as force, repetition, posture
[24-26] and specific combined elbow exposure, such as
combined elbow flexion/extension, wrist bending and
perceived physical exertion may lead to LE [27,28]. These
factors are not only risk factors for developing LE, but also
indicators of poor prognosis and prevention [29]. For
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ergonomic risk [29].
Effectiveness of patient education
The literature search identified 3 published studies for the
effectiveness of patient education on pain and disability
among individuals with LE [28-30], all of which shared
similar conclusions. The most recent paper [30] concluded
that a structured physiotherapy treatment programme,
that included ergonomic advice, was more effective than
corticosteroid injections and NSAIDs, the major findings
being that the intervention group had less pain than
patients treated with corticosteroid injections or NSAIDs
and experienced better function than those treated with
corticosteroid injections. Furthermore, the intervention
group had a lower recurrence and fewer sick leave days.
Pharmacological therapy
First line
Non-steroidal anti-inflammatory drugs (NSAIDs) via oral
administration have been used extensively for many years
to treat pain associated with LE. There is some evidence
for a short term benefit of NSAIDs (2 weeks) with a
decrease of pain and function, but this benefit was not
sustained [31,32]. However, there is little evidence to
support the use of oral NSAIDs in the long term.
Prophylaxis of gastrointestinal bleedings (GI)
Numerous RCTs and meta-analyses have demonstrated
that NSAIDs are associated with a greater risk of GI
bleedings. Exposure to NSAIDs has been associated with a
2.2 to 5.4 greater risk of various adverse GI events [33]. A
variety of factors such as older age (age ≥75), peptic ulcer
disease, history of adverse GI events, and concomitant
therapy with anticoagulants or corticosteroids, may exacer-
bate the NSAID-associated risk for GI toxicity [34]. One
meta-analysis of 112 RCTs [35] found that gastroprotective
strategies such as proton pump inhibitor (PPI) reduce the
risk of symptomatic ulcers, and misoprostol reduces the
risk of serious GI complications.
Physical therapy
First line
Therapeutic exercises Numerous RCTs have evaluated
the effects of exercise on LE. Four SRs [24,25,36-38]
reached similar conclusions. The most recent SR [36]
evaluated the effect of different exercises in LE on pain
and disability. Of the 12 included studies, 9 addressed
the effects of isotonic (eccentric/concentric) exercises,
2 studied the effect of isometrics and one studied iso-
kinetic exercises. All studies reported that resistance
exercises resulted in substantial improvement in pain
and grip strength.The most recent RCT evaluated the short-term effects
of daily eccentric exercises on functional pain-free hand
strength in subjects with long-term LE [25]. The exercise
program included 2×8–12 repetitions once a day during
the first week, while the instruction for the following
2 weeks was to progress to twice daily. At the end of the
intervention, the exercise group had significantly higher
pain-free hand-grip strength and higher pain-free hand-
extensor strength, and in the exercise group the proportion
of cases with LE decreased by 66% at the end of the
intervention, whereas in controls they decreased by 21%.
Manual therapy One SR [26] showed that lateral-glide
mobilization with movement technique had positive effects
for pain relief and restoration of function in patients with
LE. One RCT [39] studied the effect of applied mobilization
techniques using a program of six repetitions performed
with a 15 second rest interval between repetitions. This
study demonstrated a significant and substantial increase in
painfree grip strength of 58% (of the order of 60 Newton)
in the treatment group but not in the placebo or control.
Laser therapy The most recent meta-analysis [40]
assessed the clinical effectiveness of Low Level Laser
Therapy (LLLT), the relevance of irradiation parameters
to outcomes, and the validity of current dosage recom-
mendations for the treatment of tendinopathy. The
review included 25 relevant studies, 13 investigated the
effectiveness of LLLT for LE of which 6 showed positive
results. As summarized, the positive results evidenced a
recommended dosage for the management of LE which
was a wavelength of 904 nm and power densities that lay
between 2-100 mW/cm2.
Time of referral
NSAIDs are usually prescribed for 2 weeks [31,32], and
corticosteroid injections [41,42] are often used if treatment
by oral medication and other non-operative interventions
have failed. Often, physical therapy is a first option to
referral when they are not effective. There is no available
evidence of an adequate time of referral after oral NSAIDs;
however, the evidence to-date suggests that early multi-
modal programmes of physical therapy should be rec-
ommended after corticosteroid injections.
A RCT [43] supported that the combined approach
is preferred to that of injection alone. This study dem-
onstrated that a physical therapy program 1–2 weeks
following injection comprising education, 8 sessions of
manual therapy techniques (Mobilization With Move-
ment), concentric-eccentric exercises and active home
exercises improved the long term efficacy and reduced the
recurrence rates. The, benefits gained by adding physio-
therapy to injection outweighed the costs associated with
injection alone, furthermore the cost-effectiveness of the
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There is a growing body of supporting evidence for this
conservative approach, mainly for patients with LE with
refractory symptoms after physical therapy management.
Four SRs [42,44-46] have described the clinical efficacy
and risk of adverse events of PRP for treatment of LE.
The most recent meta-analysis [46] identified that the
effects of PRP injections were statistically superior to
placebo. Regarding the injection method, the recommen-
dations were to collect an amount of 25 ml of autolo-
gous blood to obtain an average of 3.5 cc of plasma, and
it was not deemed necessary to use calcium or thrombin
prior activation of platelets. For the injection technique
it was recommended to perform the infiltration into the
extensor digitorum communis tendon using the peppering
technique.
Surgery
Four SRs [8,47-49] have studied the effectiveness of surgi-
cal treatment for LE and they reported similar conclusions.
Surgical options (percutaneous, open and arthroscopic
techniques) were effective and safe interventions in re-
lieving pain and restoring function in cases where non-
operative approaches failed. However, these studies were
unable to support the superiority of one surgical procedure
over another.
Discussion
This paper summarizes the development of evidence-based
QMs for measuring degree of implementation of best
practices recommendations for patients with LE. Over a
period of one year, 12 QMs were developed and evaluated
by a panel according to methodological requirements
based on recommendations from the literature [13,14].
In our literature review we appreciated a considerable
availability of systematic reviews including patients with
LE [8,24,26-28,31,36,40,41,44-46,49]. However, we found
none containing specific clinical practice guidelines or
clinical quality indicators of LE care. This finding is sur-
prising when compared with the existing tools for quality
assessment of other health conditions, such as diabetes,
cardiovascular disease, arthritis or low back pain [50-53].
Thus, to our knowledge, the QMs we show here may
provide a first step in filling the relative void of quality
assessment for LE care.
Although we were able to find solid evidence to support
a link between the processes of care described in some
QMs and meaningful patient outcomes, no such evidence
exists for others, for example, for QMs related to pain and
functional assessment. A possible explanation for this lackof evidence could be because these processes were
traditionally assumed to be so essential to care that
clinical trials assessing their importance have not been
performed [22]. Therefore, although we could not find
supporting evidence, the expert panel rated these QMs as
valid measures of quality because assessment of these
parameters is necessary to direct therapeutic approaches.
Most of the QMs must be measured only for some
individuals with LE. For this reason, we constructed
many QMs including in the denominator and numerator
only individuals with LE who should receive the indicated
care. For example, not all patients with LE and NSAIDs
should receive prophylaxis of GI bleedings by gastropro-
tective strategies, only those who are of an older age
(age ≥75), with a history of adverse GI events, and con-
comitant therapy with anticoagulants or corticosteroids.
In a similar way, not all patients with NSAIDs should re-
ceive a multimodal program of physical therapy within
14 days, only those who received a corticosteroid injection.
The set of QMs we present here involves multidiscip-
linary interventions. All QMs are under control of the
professionals whose performance is evaluated, so that it
is possible for them to improve that performance. When
using these measures for quality improvement purposes
within an institution or facility, a baseline assessment of
current practice is recommended to better understand the
quality problem and to provide motivation for change.
Baseline results should also be used to establish a basis for
comparison across institutional units or over time [51,54].
Our study had its strengths and limitations. The main
strengths are related to the development process. We
decided to develop potential QMs using a standardized,
rigorous, approved, evidence-based approach following
previously defined recommendations to ensure high
methodological quality and maximal clearness of our
outcomes [13,14,55]. Furthermore, the QMs were devel-
oped by a multidisciplinary panel of experts to guarantee a
wide acceptance of the results by institutions and organi-
zations engaged in LE care. Additionally, a pilot study was
implemented to assure that measuring performance of
health care providers with those QMs is feasible and
reliable. The findings obtained should be interpreted in
light of the limitations of the study. First, many medical
records were lacking specific information regarding the
history of adverse GI events, and the use of concomitant
therapy with anticoagulants or corticosteroids. Conse-
quently, problems of feasibility arose for measuring
prophylaxis and time of referral QMs, and sample size for
the reliability study was lower than desirable. Secondly, only
one patient received PRP and three had a process for longer
than one year. Thus, analyses for reliability of surgery and
PRP QMs were not conducted here. Therefore, while these
analyses can be performed in upcoming studies, the use of
surgery and PRP QMs may warrant caution.
Minaya-Muñoz et al. BMC Musculoskeletal Disorders 2013, 14:310 Page 9 of 10
http://www.biomedcentral.com/1471-2474/14/310Conclusions
This is the first study to develop and evaluate QMs for
patients with LE.
The QMs we present were developed to assess quality
and not to represent guidelines of optimal care. However,
as there is no published CPG in the literature to-date, the
evidence-based recommendations identified in our review
could also be useful for developing a CPG to describe a
range of diagnostic and therapeutic processes that might
be considered best practices.
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